Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
Purpose: This study aimed to evaluate whether higher doses of consolidation radiation therapy (RT), which have been traditionally recommended for osseous sites in diffuse large B-cell lymphoma (DLBCL), are still necessary. Methods and materials: Patients with DLBCL with osseous involvement treated w...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-07-01
|
| Series: | Advances in Radiation Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452109419300405 |
| _version_ | 1818115503310241792 |
|---|---|
| author | Jessica W. Lee, MD Leonard R. Prosnitz, MD Alexandra Stefanovic, MD Chris R. Kelsey, MD |
| author_facet | Jessica W. Lee, MD Leonard R. Prosnitz, MD Alexandra Stefanovic, MD Chris R. Kelsey, MD |
| author_sort | Jessica W. Lee, MD |
| collection | DOAJ |
| description | Purpose: This study aimed to evaluate whether higher doses of consolidation radiation therapy (RT), which have been traditionally recommended for osseous sites in diffuse large B-cell lymphoma (DLBCL), are still necessary. Methods and materials: Patients with DLBCL with osseous involvement treated with first-line chemotherapy followed by consolidation RT between 1995 and 2016 were reviewed. The primary endpoint was 5-year freedom from local recurrence, estimated using the Kaplan-Meier method. Outcomes based on the RT dose received were also assessed. Results: A total of 51 patients were identified. The most common chemotherapy regimens were rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (80%) and cyclophosphamide, doxorubicin, vincristine, and prednisone (12%) with a median of 6 cycles (range, 3-8 cycles). After chemotherapy, 82% of patients achieved a complete response (CR), and 18% achieved a partial response (PR). All patients in PR were deemed appropriate for consolidation RT. The median dose was 29 Gy (24 Gy for CR; 36 Gy for PR). After a median follow-up of 86 months, 8 patients relapsed, with 2 relapses in the RT field after consolidation RT of 30 and 39.6 Gy, respectively. Overall, the 5-year freedom from local recurrence was 96% (95% confidence interval [CI], 91%-100%), disease-free survival was 76% (95% CI, 65%-89%), and overall survival was 86% (95% CI, 76%-96%). No dose-response relationship was observed. Conclusions: In patients with DLBCL with osseous involvement who achieved a CR after first-line chemotherapy, 20 to 30 Gy of consolidation RT led to high rates of local control. Higher doses should be reserved for patients in PR. |
| first_indexed | 2024-12-11T04:07:39Z |
| format | Article |
| id | doaj.art-9cd3380a0d9844b6a7c0208b9403f4ad |
| institution | Directory Open Access Journal |
| issn | 2452-1094 |
| language | English |
| last_indexed | 2024-12-11T04:07:39Z |
| publishDate | 2019-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Advances in Radiation Oncology |
| spelling | doaj.art-9cd3380a0d9844b6a7c0208b9403f4ad2022-12-22T01:21:29ZengElsevierAdvances in Radiation Oncology2452-10942019-07-0143507512Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?Jessica W. Lee, MD0Leonard R. Prosnitz, MD1Alexandra Stefanovic, MD2Chris R. Kelsey, MD3Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina; Corresponding author. Department of Radiation Oncology, DUMC 3085, Durham, NC 27710.Department of Radiation Oncology, Duke University Medical Center, Durham, North CarolinaDepartment of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North CarolinaDepartment of Radiation Oncology, Duke University Medical Center, Durham, North CarolinaPurpose: This study aimed to evaluate whether higher doses of consolidation radiation therapy (RT), which have been traditionally recommended for osseous sites in diffuse large B-cell lymphoma (DLBCL), are still necessary. Methods and materials: Patients with DLBCL with osseous involvement treated with first-line chemotherapy followed by consolidation RT between 1995 and 2016 were reviewed. The primary endpoint was 5-year freedom from local recurrence, estimated using the Kaplan-Meier method. Outcomes based on the RT dose received were also assessed. Results: A total of 51 patients were identified. The most common chemotherapy regimens were rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (80%) and cyclophosphamide, doxorubicin, vincristine, and prednisone (12%) with a median of 6 cycles (range, 3-8 cycles). After chemotherapy, 82% of patients achieved a complete response (CR), and 18% achieved a partial response (PR). All patients in PR were deemed appropriate for consolidation RT. The median dose was 29 Gy (24 Gy for CR; 36 Gy for PR). After a median follow-up of 86 months, 8 patients relapsed, with 2 relapses in the RT field after consolidation RT of 30 and 39.6 Gy, respectively. Overall, the 5-year freedom from local recurrence was 96% (95% confidence interval [CI], 91%-100%), disease-free survival was 76% (95% CI, 65%-89%), and overall survival was 86% (95% CI, 76%-96%). No dose-response relationship was observed. Conclusions: In patients with DLBCL with osseous involvement who achieved a CR after first-line chemotherapy, 20 to 30 Gy of consolidation RT led to high rates of local control. Higher doses should be reserved for patients in PR.http://www.sciencedirect.com/science/article/pii/S2452109419300405 |
| spellingShingle | Jessica W. Lee, MD Leonard R. Prosnitz, MD Alexandra Stefanovic, MD Chris R. Kelsey, MD Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites? Advances in Radiation Oncology |
| title | Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites? |
| title_full | Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites? |
| title_fullStr | Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites? |
| title_full_unstemmed | Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites? |
| title_short | Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites? |
| title_sort | are higher doses of consolidation radiation therapy necessary in diffuse large b cell lymphoma involving osseous sites |
| url | http://www.sciencedirect.com/science/article/pii/S2452109419300405 |
| work_keys_str_mv | AT jessicawleemd arehigherdosesofconsolidationradiationtherapynecessaryindiffuselargebcelllymphomainvolvingosseoussites AT leonardrprosnitzmd arehigherdosesofconsolidationradiationtherapynecessaryindiffuselargebcelllymphomainvolvingosseoussites AT alexandrastefanovicmd arehigherdosesofconsolidationradiationtherapynecessaryindiffuselargebcelllymphomainvolvingosseoussites AT chrisrkelseymd arehigherdosesofconsolidationradiationtherapynecessaryindiffuselargebcelllymphomainvolvingosseoussites |